Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year ...

Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...

In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of ...

Melissa Leichter, a Novo Nordisk executive, describes the distinct skills and mindset needed to succeed in bringing rare disease treatments to market.

Over the past decade, advances in drug discovery and clinical development have led to a rise in the number of approved therapies, resulting in an increasingly competitive marketplace. These evolving ...

E. Magnus Ohman, vice president of global development, general medicine, Amgen, reflects on the remarkable evolution of North Carolina's biotechnology sector, tracing its growth from humble origins to ...

In the 1980s, North Carolina emerged as a hub for biotechnology, largely due to the establishment of the North Carolina Biotechnology Center (NCBiotech). A state-supported, accelerator-style entity, ...

The brain cancer therapy recently approved by the FDA, Voranigo (vorasidenib), was developed from research by Duke University’s Darell Bigner and Johns Hopkins University's Bert Vogelstein and ...

We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...